APA (7th ed.) Citation

DE, J., JT, H., NA, R., S, A., EJ, W., KE, W., . . . Reeves, K. R. (2006). Efficacy of varenicline, an alpha4ß2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: A randomized controlled trial [corrected] [published erratum appears in JAMA 2006 Sep 20;296(11):1355]. JAMA: Journal of the American Medical Association, 296(1), 56. https://doi.org/10.1001/jama.296.1.56

Chicago Style (17th ed.) Citation

DE, Jorenby, et al. "Efficacy of Varenicline, an Alpha4ß2 Nicotinic Acetylcholine Receptor Partial Agonist, Vs Placebo or Sustained-release Bupropion for Smoking Cessation: A Randomized Controlled Trial [corrected] [published Erratum Appears in JAMA 2006 Sep 20;296(11):1355]." JAMA: Journal of the American Medical Association 296, no. 1 (2006): 56. https://doi.org/10.1001/jama.296.1.56.

MLA (9th ed.) Citation

DE, Jorenby, et al. "Efficacy of Varenicline, an Alpha4ß2 Nicotinic Acetylcholine Receptor Partial Agonist, Vs Placebo or Sustained-release Bupropion for Smoking Cessation: A Randomized Controlled Trial [corrected] [published Erratum Appears in JAMA 2006 Sep 20;296(11):1355]." JAMA: Journal of the American Medical Association, vol. 296, no. 1, 2006, p. 56, https://doi.org/10.1001/jama.296.1.56.